Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Status:
Terminated
Trial end date:
2015-11-13
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to determine the safety and efficacy of eculizumab in the
prevention of antibody-mediated rejection (AMR) in sensitized recipients of a living donor
kidney transplant requiring desensitization therapy.